Why the study?
Standard care for acute decompensated heart failure has remained largely unchanged for 45 years, leaving gaps in knowledge regarding effective interventions to support transitions of care.
This review highlights the potential of structural heart disease interventions to improve survival, outcomes, and quality of life for patients with advanced heart failure.
Persistent gaps in HF transition care warrant caution with unproven strategies; leaves open need for targeted trials beyond standard decongestion.
Heart failure (HF) is a leading cause of hospitalisation and healthcare costs worldwide. Acute decompensated heart failure accounts for more than 1 million hospitalisations in the US. Despite advances in the quality of acute and chronic HF disease management, gaps in knowledge about effective interventions to support the transition of care for patients with HF remain. Despite multiple trials of promising therapies, standard care consists of decongestion with IV diuretics and haemodynamic support with vasodilators and inotropes and this has remained largely unchanged during the past 45 years. Newer advances in medical innovations and structural heart disease interventions have now given promise to improved survival, outcomes and quality of life for patients with advanced HF of multiple aetiologies. In this article, we focus on structural interventions in the treatment of patients with HF.
No takes yet. Share an insight, caveat, or question.
Park et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: